<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sagimet Biosciences Inc. Series A Common Stock — News on 6ix</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock</link>
<description>Latest news and press releases for Sagimet Biosciences Inc. Series A Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 11:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sagimet-biosciences-inc-series-a-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835bf7178dffbe2df118128.webp</url>
<title>Sagimet Biosciences Inc. Series A Common Stock</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock</link>
</image>
<item>
<title>Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-pricing-of-dollar1750-million-underwritten-offering-of-series-a-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-pricing-of-dollar1750-million-underwritten-offering-of-series-a-common-stock</guid>
<pubDate>Mon, 27 Apr 2026 11:15:00 GMT</pubDate>
<description>SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the pricing of an underwritten offering of 29,166,700 shares of its Series A common stock at a price of $6.00 per share. The gross proceeds from the offering are expected to be approximately $175.0 million, before deducting underwriting discounts and commissi</description>
</item>
<item>
<title>Sagimet Biosciences Provides Strategic and Corporate Updates</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-provides-strategic-and-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-provides-strategic-and-corporate-updates</guid>
<pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
<description>Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Further MASH development to be undertaken only upon securing non-dilutive funding Sagimet to host a KOL event and webcast, April 30 at 2 pm ET SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel</description>
</item>
<item>
<title>Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-appointment-of-andreas-grauer-md-as-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-appointment-of-andreas-grauer-md-as-chief-medical-officer</guid>
<pubDate>Mon, 20 Apr 2026 11:00:00 GMT</pubDate>
<description>SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet’s prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effecti</description>
</item>
<item>
<title>Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-poster-and-oral-presentations-at-the-fueling-mash-metabolic-drivers-and-inflammatory-crosstalk-keystone-symposium-and-inducement-grant-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-poster-and-oral-presentations-at-the-fueling-mash-metabolic-drivers-and-inflammatory-crosstalk-keystone-symposium-and-inducement-grant-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel</description>
</item>
<item>
<title>Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-updates</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH</description>
</item>
<item>
<title>Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-participation-two-120000283</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-participation-two-120000283</guid>
<pubDate>Thu, 05 Feb 2026 12:00:00 GMT</pubDate>
<description>SAN MATEO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY, on February 11, 2026, with a fireside chat at 10am ET (link here).Oppenheimer 36th Annual Healthcare Life Sciences Conferen</description>
</item>
<item>
<title>Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-announces-positive-52-week-120000543</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-announces-positive-52-week-120000543</guid>
<pubDate>Mon, 02 Feb 2026 12:00:00 GMT</pubDate>
<description>SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a press release on January 29th reporting positive topline results in the open-label Phase 3 trial evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne. Denifanstat is a once-d</description>
</item>
<item>
<title>Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/biotech-veteran-and-virologist-joins-cancervax-as-senior-scientific-advisor</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/biotech-veteran-and-virologist-joins-cancervax-as-senior-scientific-advisor</guid>
<pubDate>Tue, 27 Jan 2026 08:00:00 GMT</pubDate>
<description>Dr. George Kemble, former AstraZeneca executive, to advise the Company on immunological and viral strategies for its novel cancer treatment platformLehi, Utah, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, January 27, 2026 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that George Kemble, PhD will serve as a Senior Scientific Advisor. Dr. Kemble is a veteran biotech executive and scientist</description>
</item>
<item>
<title>Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-poster-presentation-120000270</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-poster-presentation-120000270</guid>
<pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
<description>SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will be presenting a poster at the upcoming 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah. The poster will focus on the observed anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients in the Phase 2b FASCINAT</description>
</item>
<item>
<title>Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-positive-results-120000895</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-positive-results-120000895</guid>
<pubDate>Thu, 18 Dec 2025 12:00:00 GMT</pubDate>
<description>The combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the combinationA Phase 2 trial of a denifanstat/resmetirom combination in F4 MASH patients is planned to initiate in 2H 2026 SAN MATEO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced p</description>
</item>
<item>
<title>Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-tapi-announce-global-120000245</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-tapi-announce-global-120000245</guid>
<pubDate>Wed, 17 Dec 2025 12:00:00 GMT</pubDate>
<description>License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applicationsCollaboration supports Sagimet’s fixed-dose combination (FDC) program currently in clinical developmentSagimet’s Phase 1 pharmacokinetic (PK) trial of combination of denifanstat and resmetirom is underway with topline data anticipated by the end of 2025Sagimet anticipates selecting one of the innovative form</description>
</item>
<item>
<title>Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-license-partner-ascletis-announced-120300795</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-license-partner-ascletis-announced-120300795</guid>
<pubDate>Wed, 10 Dec 2025 12:03:00 GMT</pubDate>
<description>SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a December 10 statement that China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for denifanstat for the treatment of moderate to severe acne. Sagimet has granted an exclusive lic</description>
</item>
<item>
<title>Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-inducement-grants-210500023</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-inducement-grants-210500023</guid>
<pubDate>Tue, 09 Dec 2025 21:05:00 GMT</pubDate>
<description>SAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of three employees, the Compensation Committee of Sagimet’s Board of Directors approved inducement grants of 42,800 stock options in aggregate to purchase shares of the Company’s Series A common stock as determined based on</description>
</item>
<item>
<title>Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-participate-8th-annual-120000979</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-participate-8th-annual-120000979</guid>
<pubDate>Thu, 20 Nov 2025 12:00:00 GMT</pubDate>
<description>SAN MATEO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the 8th Annual Evercore ISI Healthcare Conference on Tuesday, December 2, 2025, in Coral Gables, Florida, with a fireside chat at 12:55pm ET (link here). A webcast of the fireside chat will be available in the Investors & Me</description>
</item>
<item>
<title>Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-reports-third-quarter-123000374</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-reports-third-quarter-123000374</guid>
<pubDate>Thu, 13 Nov 2025 12:30:00 GMT</pubDate>
<description>Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Ascletis announced completion of its pre-NDA consultation with China’s NMPA and plans to submit an NDA for denifanstat in China for treatment of moderate-to-severe acne vulgaris SAN MATEO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-sta</description>
</item>
<item>
<title>Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-presents-two-denifanstat-120000230</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-presents-two-denifanstat-120000230</guid>
<pubDate>Mon, 10 Nov 2025 12:00:00 GMT</pubDate>
<description>A secondary analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis, inflammation and steatosis in advanced qF4 MASH patients as measured by artificial intelligence (AI) digital pathology In a second poster, spatial computational histology relying on baseline fibrosis features was used to predict response to denifanstat SAN MATEO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel</description>
</item>
<item>
<title>Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/denifanstat-achieved-all-endpoints-in-the-treatment-of-moderate-to-severe-acne-in-phase-3-clinical-trial-in-acne-in-china-a-presentation-at-the-2025-fall-clinical-dermatology-conference</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/denifanstat-achieved-all-endpoints-in-the-treatment-of-moderate-to-severe-acne-in-phase-3-clinical-trial-in-acne-in-china-a-presentation-at-the-2025-fall-clinical-dermatology-conference</guid>
<pubDate>Fri, 24 Oct 2025 04:00:00 GMT</pubDate>
<description>Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by</description>
</item>
<item>
<title>Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-participation-three-110000329</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-participation-three-110000329</guid>
<pubDate>Tue, 14 Oct 2025 11:00:00 GMT</pubDate>
<description>SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in three upcoming investor conferences. H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025, with a fireside chat available starting October 21 at 7am ET (link here).Guggenheim 2nd Annual Healthcare</description>
</item>
<item>
<title>Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-upcoming-presentation-110000421</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-upcoming-presentation-110000421</guid>
<pubDate>Tue, 07 Oct 2025 11:00:00 GMT</pubDate>
<description>SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that analyses of the Phase 2b FASCINATE-2 study showing that denifanstat elicited fibrosis improvement in patients with advanced fibrosis will be presented at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2025, taking pla</description>
</item>
<item>
<title>Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination</title>
<link>https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-dosing-first-110000054</link>
<guid isPermaLink="true">https://6ix.com/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-dosing-first-110000054</guid>
<pubDate>Wed, 01 Oct 2025 11:00:00 GMT</pubDate>
<description>Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are anticipated in the first half of 2026 SAN MATEO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company h</description>
</item>
</channel>
</rss>